LBIRD Lumibird SA
Lumibird SA designs, manufactures, and sells various lasers for scientific, industrial, and medical applications in France, Hong Kong, the United States, Germany, South Korea, China, and Austria. The company operates through Photonics and Medical divisions. It offers fiber lasers and amplifiers, high power fiber lasers, and solid-state lasers, laser diodes and components; and doppler wind LiDAR, time-of-flight LiDAR and rangefinders, military laser rangefinders, and medical and ophthalmological solutions. The company serves defense and space, environment, topography and safety, industry and science, and science and healthcare industries. Lumibird SA was incorporated in 1970 and is headquartered in Lannion, France. Lumibird SA is a subsidiary of ESIRA.…
Industry Peers
Diagnostics & ResearchKey Statistics
About Lumibird (EPA: LBIRD)
›
Lumibird (EPA: LBIRD) is listed on Euronext Paris, where its shares trade in EUR. It belongs to the Diagnostics & Research industry, part of the Healthcare sector, and reports about 1,078 employees.
The shares were at 24.80 EUR on 19 November 2026, up 27.2% over 52 weeks. Its 52-week range is 18.75 EUR to 28.70 EUR: the price is 13.6% below the high and 32.3% above the low.
At a market capitalisation of 547.23M EUR, it trades at 38.8 times trailing earnings and 30.4 times forward earnings. The median trailing P/E of its 18 largest Diagnostics & Research peers is 35.8, so LBIRD is valued in line with them. It pays a dividend yielding 1.54%, against a median of 0.73% among the dividend payers in that peer group.
Lumibird reports return on equity of 6.8%, an operating margin of 10.6% and revenue up 5.9% year over year.
Its debt exceeds its cash by 92.60M EUR, a debt-to-equity ratio of 0.71. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. 4 analysts cover the stock; their mean price target of 30.88 EUR is 24.5% above the current price.